Hyunseok Kang

25PUBLICATIONS
74CO-AUTHORS
Biologically active moleculesPredictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Solid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Aug 03, 2026
A Selective CK1α Degrader Targets Acute Myeloid Leukemia and Spares Normal Hematopoietic Cells.

|Jun 18, 2026
Metastatic Lymph Node Status Is Associated With Progression-Free Survival in Oral Cavity Squamous Cell Carcinoma Treated With Pembrolizumab.

|May 25, 2026
Potent Anti-Tumor Activity of the AXL-Targeted Antibody-Drug Conjugate, Mipasetamab Uzoptirine (ADCT-601), in Preclinical Models of Adenoid Cystic Carcinoma.

|May 10, 2026
Neutrophil-To-Lymphocyte Ratio and Survival in Pembrolizumab-Treated Oropharyngeal Cancer.

|May 05, 2026
Potent anti-tumor activity of the AXL-targeted antibody-drug conjugate, mipasetamab uzoptirine (ADCT-601), in preclinical models of adenoid cystic carcinoma.

|Sep 30, 2024
CYLD Alterations Are Associated With Metastasis and Poor Prognosis in Human Papilloma Virus-Positive Head and Neck Cancer.

Zhibin Cui, Hyunseok Kang, Hua Li

Pageof 5

Frequent Collaborators

5 joint publications

Patrick K Ha

5 joint publications

Rex H Lee

3 joint publications

Katherine C Wai

3 joint publications

Chase M Heaton